DexCom, Inc. (DXCM)
After hours:
| Previous Close | 69.71 |
| Open | 69.83 |
| Bid | 68.46 x 300 |
| Ask | 68.57 x 400 |
| Day's Range | 68.06 - 70.01 |
| 52 Week Range | 62.34 - 142.00 |
| Volume | |
| Avg. Volume | 5,350,598 |
| Market Cap | 27.47B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | 42.58 |
| EPS (TTM) | 1.61 |
| Earnings Date | Oct 24, 2024 - Oct 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 97.25 |
Business WireDexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Dawn Mission
SAN DIEGO, September 10, 2024--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better understand the effects of spaceflight on human health.
Insider MonkeyHere’s Why DexCom (DXCM) Fell in Q2
Investment advisory firm Ithaka Group released the “Ithaka US Growth Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. The second quarter of 2024 saw a surge in optimism among global markets, driven by the anticipation of a looser monetary policy from the Federal Reserve and the ongoing development prospects presented by […]
Business WireDexcom to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium
EDINBURGH, Scotland, September 04, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will spotlight the significant benefits of its innovative CGM technology at an upcoming symposium during the European Association for the Study of Diabetes (EASD) Conference on Monday, 9th September, 1300 – 1430 CEST. The symposium will feature expert panellists from endocrinology Prof. Michael Joubert MD PhD, France, primary care, Prof.
